featured
Dr. Clyde Yancy Contextualizes Key Trials From ESC 2017
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- ESC 2017: The Interleukin-1β Inhibitor Canakinumab Cuts Cardiovascular Disease and Lung Cancer Risk by Reducing Inflammation - CANTOS Trial
- ESC 2017: Catheter Ablation Improves Outcomes in Patients With Heart Failure and Atrial Fibrillation - CASTLE-AF Trial
- Participatory Role of Inflammation in Atherosclerotic Disease Confirmed by CANTOS
Disclosure statements are available on the authors' profiles: